[ Impact of CCND1 A870 G polymorphism on <font color="red">acute_2</font> <font color="red">adverse_2</font> <font color="red">events_2</font> in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ] . 
<br>
<br> OBJECTIVE The purpose of this study was to investigate the <font color="red">association_1</font> <font color="red">between_1</font> <font color="red">single_1</font> <font color="red">nucleotide_1</font> <font color="red">polymorphism_1</font> <font color="red">(_1</font> <font color="red">SNP_1</font> <font color="red">)_1</font> <font color="red">of_1</font> <font color="red">CCND1_1</font> <font color="red">A870_1</font> <font color="red">G_1</font> <font color="red">and_1</font> <font color="red">acute_2</font> <font color="red">adverse_2</font> <font color="red">events_2</font> <font color="red">(_2</font> <font color="red">AEs_2</font> <font color="red">)_2</font> in postoperative rectal cancer patients who received capecitabine - based postoperative chemoradiotherapy ( CRT ) . 
<br> METHODS Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin were accumulated and prostectively studied in this study . The patients were randomly divided into two groups . Two hundred and twenty - eight patients were treated with concurrent capecitabine and radiotherapy ( Cap - CRT ) , and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy ( Cap - Oxa - CRT ) . <font color="red">Adverse_2</font> <font color="red">events_2</font> <font color="red">were_1</font> <font color="red">graded_1</font> <font color="red">according_1</font> <font color="red">to_1</font> <font color="red">the_1</font> <font color="red">Common_1</font> <font color="red">Terminology_1</font> <font color="red">Criteria_1</font> <font color="red">for_1</font> <font color="red">Adverse_1</font> <font color="red">Events_1</font> <font color="red">,_1</font> <font color="red">v._1</font> <font color="red">3.0_1</font> <font color="red">(_1</font> <font color="red">CTCAE_1</font> <font color="red">v3.0_1</font> <font color="red">)_1</font> <font color="red">._1</font> The genotype of CCND1 A870 G in the patients was detected by polymerase chain reaction - based restriction fragment length polymorphism ( PCR - RFLP ) analysis . The associations between the SNP and <font color="red">acute_1</font> <font color="red">AEs_1</font> were indicated by odds ratios ( ORs ) and 95% confidence intervals ( CIs ) , which were computed with logistic regression model . 
<br> RESULTS <font color="red">A_1</font> <font color="red">total_1</font> <font color="red">of_1</font> <font color="red">136_1</font> <font color="red">patients_1</font> <font color="red">presented_1</font> <font color="red">severe_1</font> <font color="red">AEs_2</font> <font color="red">._2</font> <font color="red">Among_1</font> <font color="red">them_1</font> <font color="red">the_1</font> <font color="red">frequencies_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">three_1</font> <font color="red">genotypes_1</font> <font color="red">GG_1</font> <font color="red">,_1</font> <font color="red">GA_1</font> <font color="red">and_1</font> <font color="red">AA_1</font> <font color="red">were_1</font> <font color="red">16.9%_1</font> <font color="red">,_1</font> <font color="red">50.7%_1</font> <font color="red">and_1</font> <font color="red">32.4%_1</font> <font color="red">,_1</font> <font color="red">compared_1</font> <font color="red">with_1</font> <font color="red">24.6%_1</font> <font color="red">,_1</font> <font color="red">48.1%_1</font> <font color="red">and_1</font> <font color="red">27.3%_1</font> <font color="red">,_1</font> <font color="red">respectively_1</font> <font color="red">,_1</font> <font color="red">among_1</font> <font color="red">the_1</font> <font color="red">patients_1</font> <font color="red">without_1</font> <font color="red">severe_1</font> <font color="red">AEs_1</font> <font color="red">._1</font> <font color="red">Diarrhea_2</font> <font color="red">was_2</font> <font color="red">the_2</font> <font color="red">most_2</font> <font color="red">common_2</font> <font color="red">AE_2</font> <font color="red">,_2</font> <font color="red">and_1</font> <font color="red">severe_1</font> <font color="red">diarrhea_1</font> <font color="red">occurred_1</font> <font color="red">in_1</font> <font color="red">109_1</font> <font color="red">patients_1</font> <font color="red">._1</font> <font color="red">The_1</font> <font color="red">frequencies_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">three_1</font> <font color="red">genotypes_1</font> <font color="red">GG_1</font> <font color="red">,_1</font> <font color="red">GA_1</font> <font color="red">and_1</font> <font color="red">AA_1</font> <font color="red">were_1</font> <font color="red">15.6%_1</font> <font color="red">,_1</font> <font color="red">47.7%_1</font> <font color="red">and_1</font> <font color="red">36.7%_1</font> <font color="red">among_1</font> <font color="red">these_1</font> <font color="red">patients_1</font> <font color="red">,_1</font> <font color="red">compared_1</font> <font color="red">with_1</font> <font color="red">24.4%_1</font> <font color="red">,_1</font> <font color="red">49.5%_1</font> <font color="red">and_1</font> <font color="red">26.1%_1</font> <font color="red">,_1</font> <font color="red">respectively_1</font> <font color="red">,_1</font> <font color="red">among_1</font> <font color="red">patients_1</font> <font color="red">without_1</font> <font color="red">severe_1</font> <font color="red">diarrhea_1</font> <font color="red">._1</font> Multivariate logistic regression analysis showed a 1.66-fold increased <font color="red">risk_1</font> <font color="red">for_1</font> <font color="red">severe_2</font> <font color="red">diarrhea_2</font> <font color="red">in_1</font> <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">AA_1</font> <font color="red">genotype_1</font> <font color="red">(_1</font> <font color="red">95%CI_1</font> <font color="red">1.03_1</font> <font color="red">-_1</font> <font color="red">2.67_1</font> <font color="red">,_1</font> <font color="red">P_1</font> <font color="red">=_1</font> <font color="red">0.038_1</font> <font color="red">)_1</font> <font color="red">compared_1</font> <font color="red">with_1</font> <font color="red">the_1</font> <font color="red">cases_1</font> <font color="red">with_1</font> <font color="red">GG_1</font> <font color="red">or_1</font> <font color="red">GA_1</font> <font color="red">genotypes_1</font> <font color="red">._1</font> Stratified analysis showed that in the Cap - Oxa - CRT group , patients with AA genotype showed a 2.34-fold <font color="red">increased_1</font> <font color="red">risk_1</font> <font color="red">for_1</font> <font color="red">severe_2</font> <font color="red">diarrhea_2</font> ( 95%CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap - CRT group , the <font color="red">SNP_1</font> <font color="red">was_1</font> <font color="red">not_1</font> <font color="red">associated_1</font> <font color="red">with_1</font> <font color="red">the_1</font> <font color="red">risk_1</font> <font color="red">of_1</font> <font color="red">severe_2</font> <font color="red">diarrhea_2</font> <font color="red">._2</font> <font color="red">
<br>_1</font> CONCLUSIONS <font color="red">The_1</font> <font color="red">genetic_1</font> <font color="red">polymorphism_1</font> <font color="red">of_1</font> <font color="red">CCND1_1</font> <font color="red">A870_1</font> <font color="red">G_1</font> <font color="red">might_1</font> <font color="red">be_1</font> <font color="red">a_1</font> <font color="red">potential_1</font> <font color="red">biomarker_1</font> <font color="red">for_1</font> <font color="red">predicting_1</font> <font color="red">acute_2</font> <font color="red">AEs_2</font> <font color="red">in_1</font> <font color="red">postoperative_1</font> <font color="red">stage_1</font> <font color="red">II_1</font> <font color="red">and_1</font> <font color="red">III_1</font> <font color="red">rectal_1</font> <font color="red">cancer_1</font> <font color="red">patients_1</font> <font color="red">treated_1</font> <font color="red">with_1</font> <font color="red">adjuvant_1</font> <font color="red">concurrent_1</font> <font color="red">chemoradiotherapy_1</font> <font color="red">of_1</font> <font color="red">capecitabine_1</font> <font color="red">and_1</font> <font color="red">oxaliplatin_1</font> <font color="red">._1</font> <font color="red">
<br>
<br>_1</font>